AnaptysBio/$ANAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AnaptysBio
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Ticker
$ANAB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
136
ISIN
US0327241065
Website
AnaptysBio Metrics
BasicAdvanced
$689M
-
-$4.79
-0.20
-
Price and volume
Market cap
$689M
Beta
-0.2
52-week high
$41.31
52-week low
$12.21
Average daily volume
663K
Financial strength
Current ratio
8.246
Quick ratio
8.125
Long term debt to equity
1,011.125
Total debt to equity
1,016.893
Interest coverage (TTM)
-1.62%
Profitability
EBITDA (TTM)
-99.698
Gross margin (TTM)
-50.15%
Net profit margin (TTM)
-125.70%
Operating margin (TTM)
-89.64%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-15.14%
Return on equity (TTM)
-343.83%
Valuation
Price to revenue (TTM)
6.151
Price to book
20.95
Price to tangible book (TTM)
20.95
Price to free cash flow (TTM)
-6.304
Free cash flow yield (TTM)
-15.86%
Free cash flow per share (TTM)
-371.98%
Growth
Revenue change (TTM)
387.20%
Earnings per share change (TTM)
-21.83%
3-year revenue growth (CAGR)
28.36%
10-year revenue growth (CAGR)
19.94%
3-year earnings per share growth (CAGR)
20.23%
10-year earnings per share growth (CAGR)
27.49%
What the Analysts think about AnaptysBio
Analyst ratings (Buy, Hold, Sell) for AnaptysBio stock.
Bulls say / Bears say
AnaptysBio's rosnilimab achieved positive results in a Phase 2b rheumatoid arthritis trial, demonstrating significant efficacy and favorable safety, positioning it as a potential best-in-disease therapy. (AnaptysBio News)
The company announced a stock repurchase plan in March 2025, signaling confidence in its financial position and future prospects. (AnaptysBio News)
Analysts have set an average target price of $42.55 for AnaptysBio, indicating a potential upside of over 80% from the current stock price. (Director's Talk Interviews)
AnaptysBio's ANB032 failed to meet primary and secondary endpoints in a mid-stage eczema trial, leading to the discontinuation of its development. (Reuters)
The company reported a negative return on equity of -343.83% and a free cash flow of -$60.04 million, highlighting ongoing financial challenges. (Director's Talk Interviews)
AnaptysBio's stock has experienced significant volatility, with a 52-week range between $12.38 and $40.33, reflecting market uncertainty. (Director's Talk Interviews)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AnaptysBio Financial Performance
Revenues and expenses
AnaptysBio Earnings Performance
Company profitability
AnaptysBio News
AllArticlesVideos
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Benzinga·1 month ago
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
GlobeNewsWire·1 month ago
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AnaptysBio stock?
AnaptysBio (ANAB) has a market cap of $689M as of July 08, 2025.
What is the P/E ratio for AnaptysBio stock?
The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of July 08, 2025.
Does AnaptysBio stock pay dividends?
No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next AnaptysBio dividend payment date?
AnaptysBio (ANAB) stock does not pay dividends to its shareholders.
What is the beta indicator for AnaptysBio?
AnaptysBio (ANAB) has a beta rating of -0.2. This means that it has an inverse relation to market volatility.